BC-CfE Eligibility Criteria for emtricitabine/tenofovir alafenamide (FTC/TAF; Descovy®)

All new prescriptions for emtricitabine/tenofovir alafenamide (FTC/TAF; Descovy®) require submission of an HIV Drug Treatment Program Prescription Request form. When requesting Descovy®, the prescriber should provide justification for its use on the prescription form and include appropriate documentation (i.e. laboratory or DXA scan results).

The **specific criteria** are (must meet **both** criteria A **and** B):

A. ***Cannot take abacavir***, due to HLA-B*5701 positivity, documented abacavir resistance, or documented significant abacavir intolerance; or abacavir contraindicated because of established cardiovascular disease or high estimated risk of cardiovascular disease in accordance with the Canadian Cardiovascular Society guidelines (**http://www.ccs.ca/eguidelines/Content/Topics/Dyslipidemia/_landing_page_dyslipidemia.htm**)

   OR

   Hepatitis B coinfection

AND

B. One or more of the following conditions currently, or in the past ***while receiving tenofovir disoproxil fumarate (TDF)***:

   - Estimated glomerular filtration rate (eGFR) >30 and <60 mL/min for >3 months (TAF is not licensed for individuals with eGFR <30 mL/min)
   - eGFR 60-70 mL/min but declining
   - eGFR 60-89 mL/min plus proteinuria (urine albumin to creatinine ratio [UACR]>3 mg/mmol)
   - Persistent moderate to severe hypophosphatemia (serum phosphate <0.64 mmol/L)
   - Persistent significant proteinuria (UACR >30 mg/mmol)
   - Documented osteoporosis (at least one T-score <-2.5 at the hip or spine on DXA scan)
   - In premenopausal women and men <50 years of age, a Z-score ≤-2.0
   - High (>10%) 10-year risk of major osteoporotic fracture as determined by FRAX score (**https://www.sheffield.ac.uk/FRAX/tool.aspx?country=19**)
   - Fragility fracture (atraumatic fracture or fracture resulting from minimal trauma)
   - Documented osteomalacia (laboratory and/or imaging)